Myriad Genetics (MYGN) Asset Writedowns and Impairment (2009 - 2026)

Myriad Genetics (MYGN) has reported Asset Writedowns and Impairment for 17 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $324.8 million (up 486.28% YoY), while the FY2025 annual figure was $319.4 million, up 464.31% from the prior year.
• Asset Writedowns and Impairment rose to $5.4 million in Q1 2026 per MYGN's latest filing, from $2.7 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $316.7 million in Q2 2025 and bottomed at $800000.0 in Q3 2024.
• Historically, Asset Writedowns and Impairment has averaged $44.3 million across 4 years, with a median of $6.2 million in 2022.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 2630.17% in 2025 and fell as far as 93.72% in 2025.
• Myriad Genetics' Asset Writedowns and Impairment stood at $6.2 million in 2022, then surged by 593.55% to $43.0 million in 2024, then slumped by 93.72% to $2.7 million in 2025, then surged by 100.0% to $5.4 million in 2026.
• Business Quant data shows MYGN's Asset Writedowns and Impairment at $5.4 million in Q1 2026, $2.7 million in Q4 2025, and $316.7 million in Q2 2025.